10X Genomics Stock: A Study in Market Contradictions

Robust Quarterly Earnings Met With Market Apathy

The recent performance of 10X Genomics (TXG) presents investors with a fascinating puzzle: how can a company deliver impressive quarterly results while its stock experiences a significant decline? This divergence between operational success and market sentiment has created a clear split in investor opinion, with a major institutional player making a substantial bet even as some analysts express caution.

On August 21st, 10X Genomics released its second-quarter 2025 financial results, which demonstrated considerable strength across key metrics. The company reported earnings per share of $0.28, dramatically surpassing consensus estimates that had projected a loss of $0.35 per share. Revenue performance was equally impressive, reaching $172.91 million?a 12.9% year-over-year increase that comfortably exceeded expectations.